BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IPO Watch: CombinatoRx, Incorporated And The Biological Two-Step


10/19/2005 5:12:59 PM

CombinatoRx finds itself in that familiar rock/hard-place difficulty. The rock is a lousy IPO market, which is very grudging in its valuations of development-stage biotechs, and the hard place is not having any money. The premise behind CombinatoRx is that biological pathways are often double. Thus, a drug may be efficacious against one pathway, only to have a disease make an end-run down a secondary route. To outsmart the disease, CombinatoRx screens a library of 2,000 already-approved drugs to see if a combination of any two could plausibly treat an illness even if neither one of them is currently used against the disease or if adding a second drug could increase the first drug’s effectiveness. We look at the pipeline of the company and its finances. In the last two months, most biotechs have chosen to postpone their offerings rather than reduce the IPO price down to fire-sale levels. Will CombinatoRX face the same unpleasant, lesser-of-two-evils choice?


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES